logo


Biotech Companies Look to Benefit From Transformed Patent System – MarketWatch.

NEW YORK, NY, May 15, 2012 (MARKETWIRE via COMTEX) — In recent months the Biotech Industry has become a hotbed of Merger and Acquisition (M&A) activity and speculation. As large pharmaceuticals face major patent expirations in 2012 they have looked to biotech companies to provide new streams of revenue. Given the limited amount of competing companies, the ones with quality drugs and proven technologies stand to gain the most. Five Star Equities examines the outlook for companies in the Biotech Industry and provides equity research on Advanced Cell Technology, Inc. (OBB:ACTC) and StemCells, Inc. (NASDAQ:STEM) .

Access to the full company reports can be found at:  www.FiveStarEquities.com/ACTC www.FiveStarEquities.com/STEM

The U.S. patent system will see a major change for the first time in over 60 years. The America Invents Act (AIA) will see the U.S. patent system transform from a "first to invent" to a "first to file" system. Read More

Juventas Therapeutics Enrolling Patients in Phase IIa STOP-CLI Clinical Trial
MarketWatch (press release)
JVS-100, the Company's lead product, encodes Stromal cell-Derived Factor 1 (SDF-1) which has been shown to repair damaged tissue through recruitment of circulating stem cells to the site of injury, prevention of ongoing cell death and restoration of
See all stories on this topic »
TiGenix : Business & Financial Results First Quarter 2012
Reuters
Q4, 2011 Publication of large follow-up study in leading journal confirms efficacy and safety of ChondroCelect Allogeneic stem cell platform ADMIRE-CD Phase III trial (Cx601) in complex perianal fistula on schedule Cx611 Phase IIa in rheumatoid
See all stories on this topic »
BioRestorative (BRTX): Two Huge Markets, One Solid Business Model
BiotechStockTrader.com
BioRestorative Therapies Inc. (OTCQB: BRTX), an emerging leader in autologous adult stem cell treatments for the disc/spine, metabolic disorders, and obesity, operating alongside companies like Pluristem Therapeutics Inc. (NASDAQ: PSTI) and Neuralstem
See all stories on this topic »
Gamida Cell Closes $10 Million E Financing Round Earmarked to Support the
MarketWatch (press release)
Mr. Reuven Krupik, chairman of the board of Gamida Cell said, "The investors were unanimous in their decision to reinvest, understanding the importance of bringing StemEx to market as well as maintaining the company's leadership role in the stem cell
See all stories on this topic »

 

Enhanced by Zemanta